SURFACE MODIFICATION OF POLYMERS VIA SURFACE ACTIVE AND REACTIVE END GROUPS

Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively, a multifunctional coupling agent can be used to couple the primary reactive group to a second reactive group capable of reacting with a functional group associated with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, and polymers to attain specific surface properties. The invention involves bringing reactive endgroups to the surface with surface active spacer attached to the polymer chain end. The surface active spacer allows the migration and enrichment of reactive end groups to the surface during fabrication. The invention provides medical devices having a bio-interface with anti-thrombogenic properties ...

ANTIMICROBIAL POLYMERS AND THEIR USES

Polymers with non-leaching antimicrobial activity and their use as surface coatings or bulk resins for medical devices. The antimicrobial polymers are prepared with antimicrobial moieties covalently bonded to a polymer chain end or to a polymer backbone at a side chain end. The antimicrobial moiety-containing endgroups include surface active (or surface assembling) moieties which promote enrichment of antimicrobial endgroups at the polymer surface and thus formation of an antimicrobially active surface. Polymers with built-in antimicrobial endgroups can be used as bulk resins, as antimicrobial additives, or as infection preventative coatings in the manufacture of medical devices (e.g., catheters, vascular access devices, peripheral lines, IV sites, drains, gastric feeding and tubes, and other implantable devices). Such materials can also be used as antimicrobial and antifouling coatings on structures in contact with microorganism in environments that require control of biofilm formation ...

DEVICE AND METHOD FOR RESTORATION OF THE CONDITION OF BLOOD

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

NOVEL PDMS-PVP BLOCK COPOLYMERS

Methods for preparing functionalized polyvinylpyrrolidones with polymerizable functions. Also, amphipathic polydimethylsiloxane-PVP block copolymers, such as 2. The compound of claim 1 , wherein R=butyl; “a” is from 2 to 50; R═(CH); “b”=1; X═O; R═H; R=pyrrolidinone; “d”=1-10 claim 1 ,000; R═C(CH)—O—CH—CH; Y═O; and R═CH.3. The compound of claim 1 , wherein R=butyl; “a” is from 2 to 50; R═(CH); “b”=1; X═O; R═H; R=pyrrolidinone; “d”=1-10 claim 1 ,000; R═C(CH)—O—CH—CH; Y═NH; and R═CH.4. The compound of claim 1 , wherein R=butyl; “a” is from 2 to 50; R═(CH); “b”=1; X═NH; R═H; R=pyrrolidinone; “d”=1-10 claim 1 ,000; R═C(CH); Y═O; and R═CH.5. The compound of claim 1 , wherein R=butyl; “a” is from 2 to 50; R═(CH)—O—(CH); “b”=1; X═O; R═H; R=pyrrolidinone; “d”=1-10 claim 1 ,000; R═C(CH); Y═NH; and R═CH.6. The amphipathic diblock copolymer of claim 1 , formulated for use in the preparation of silicone hydrogel lenses.7. The amphipathic diblock copolymer of claim 1 , formulated for use in the preparation of an oxygen permeable and wettable backing material for a wound healing device.8. The amphipathic diblock copolymer of claim 1 , formulated for use in the preparation of a scaffold for tissue engineering.9. The amphipathic diblock copolymer of claim 1 , formulated for use in the preparation of a component for controlled drug release. The present application is a 37 C.F.R. §1.53(b) divisional of, and claims priority to, U.S. application Ser. No. 12/531,200 (filing date: Dec. 14, 2009). Application Ser. No. 12/531,200 is the national phase under 35 U.S.C. §371 of International Application No. PCT/US2008/056825, filed on Mar. 13, 2008 which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application Ser. No. 60/895,042 filed on Mar. 15, 2007. The entire contents of each of these applications is hereby incorporated by reference.This invention relates to polymerizable poly(N-vinyl-2-pyrrolidone) (PVP) and amphipathic copolymers containing polydimethylsiloxane (PDMS) and ...

REMOVAL OF VIRULENCE FACTORS THROUGH EXTRACORPOREAL THERAPY

A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as and 1Bacillus anthracis, Pseudomonas aureginosa,Staphylococcus aureus,. A method for removal from mammalians blood of a pathogen or a toxin from said pathogen wherein said pathogen is a member selected from the group consisting of and said method comprising:a. bringing a sample of blood in contact with a carbohydrate immobilized on a solid substrate, said carbohydrate having binding affinity for said pathogen or toxin, under conditions allowing the binding of said substrate to said pathogen or toxin in said sample of blood;b. separating the sample from said substrate whereby said pathogen or said toxin is at least partially retained or said substrate and the removed sample has a reduced amount of said pathogen or toxin.2Bacillus anthracis.. The method according to claim 1 , wherein said pathogen is3. The method according to claim 1 , wherein said substrate has affinity to toxins that are capable of binding to heparin sulphate segments on syndecans.4. The method according to claim 1 , wherein said substrate has affinity to the protective antigen in anthrax toxin.5. The method according to claim 1 , wherein said solid substrate is comprised of at least one member selected from the group consisting of glass claim 1 , cellulose claim 1 , cellulose acetate claim 1 , chitin claim 1 , chitosan claim 1 , crosslinked dextran claim 1 , crosslinked agarose claim 1 , polyurethane claim 1 , polymethylmethacrylate claim 1 , polyethylene or co-polymers of ethylene and other monomers claim 1 , polyethylene imine claim 1 , polypropylene claim 1 , polysulfone claim 1 , polyacrylonitrile claim 1 , silicone and polyisobutylene.6. The method according to claim 1 , wherein said carbohydrate is heparin.7Bacillus anthracis, Pseudomonas aureginosa,Staphylococcus ...

HYDROPHILIC INTERPENETRATING POLYMER NETWORKS DERIVED FROM HYDROPHOBIC POLYMERS

A composition of matter comprising a water-swellable IPN or semi-IPN including a hydrophobic thermoset or thermoplastic polymer and an ionic polymer, articles made from such composition and methods of using such articles. The invention also includes a process for producing a water-swellable IPN or semi-IPN from a hydrophobic thermoset or thermoplastic polymer including the steps of placing an ionizable monomer solution in contact with a solid form of the hydrophobic thermoset or thermoplastic polymer; diffusing the ionizable monomer solution into the hydrophobic thermoset or thermoplastic polymer; and polymerizing the ionizable monomers to form a ionic polymer inside the hydrophobic thermoset or thermoplastic polymer, thereby forming the IPN or semi-IPN. 1. An orthopedic implant device , said implant device comprising:an IPN or semi-IPN composition having a hydrogel bearing side of a polyacrylic acid network and a polyurethane network; anda bone interface surface of an optionally porous polyurethane, with a seamless transition zone or gradient between the hydrogel bearing side and the bone interface surface.2. The orthopedic implant device of claim 1 , wherein at least one of the networks is a covalently cross-linked network.3. The orthopedic implant device of claim 2 , wherein the at least one covalently cross-linked network is the polyurethane network.4. The orthopedic implant device of claim 1 , further comprising an antioxidant.5. The orthopedic implant device of claim 1 , further comprising water.6. The orthopedic implant device of claim 5 , wherein the water forms a hydration gradient from a first portion of the composition to a second portion of the composition.7. The orthopedic implant device of claim 5 , further comprising an electrolyte dissolved in the water.8. The orthopedic implant device of claim 1 , wherein the polyacrylic acid network forms a concentration gradient from a first portion of the composition to a second portion of the composition.9. The ...

POLYURETHANE-GRAFTED HYDROGELS

An article comprising two chemically grafted polymer layers comprising a hydrogel layer and an end-functionalized polyurethane layer. The invention also includes methods of making and using the article. 1. A method of grafting a polyurethane layer to a hydrogel layer the method comprising the steps of:providing a first solution comprising either reactive hydrogel or end-functionalized polyurethane precursors;applying a second solution to the first solution wherein the second solution comprises end-functionalized polyurethane precursors if the first solution comprises hydrogel precursors and wherein the second solution comprises reactive hydrogel precursors if the first solution comprises polyurethane precursors; andpolymerizing and crosslinking the solutions to form a laminated graft polymer comprising a polyurethane layer and a hydrogel layer.2. The method of further comprising freezing the first solution to form a solidified layer.3. The method of further comprising drying the first solution to form a solidified layer.4. The method of wherein the polymerizing step comprises exposing the first and second solutions to UV light or heat.5. The method of further comprising:immersing at least part of the laminated graft polymer in a third solution, the third solution comprising hydrogel precursors different from the precursors in the first or second solutions;swelling at least part of the graft polymer; andpolymerizing the third solution to create a graft polymer comprising a polyurethane layer and an IPN layer comprising a second hydrogel network intertwined with a first hydrogel network.6. The method of wherein the third solution comprises a partial solvent for the first hydrogel and is able to swell the first hydrogel network.7. The method of wherein the hydrogel solution comprises telechelic molecules.8. The method of wherein the telechelic molecules are poly(ethylene glycol) with one or more endgroups selected from the group consisting of acrylate claim 7 , ...

Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines

The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.

METHOD FOR TREATING DRUG INTOXICATION

Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject. 1. A method for treating drug intoxication or removing a toxin in a subject in need thereof , said method comprising:contacting a sample from a subject suffering from drug intoxication or other intoxication with an adsorption media comprising a combination of activated carbon and a substrate having at least one polysaccharide adsorbent to form a cleansed sample; andinfusing the cleansed sample into the subject.2. The method of claim 1 , wherein the adsorption media and the drug form an adhering complex.3. The method of claim 2 , further comprising separating the resulting sample from the adhering complex to produce a cleansed sample with a reduced amount of drug.4. The method of claim 1 , wherein the drug is a member selected from the group consisting of analgesics claim 1 , sedatives claim 1 , hypnotics claim 1 , antipsychotics claim 1 , antidepressants cardiovascular drugs claim 1 , antihistamines claim 1 , topical preparations claim 1 , cold and cough preparations claim 1 , stimulants claim 1 , street drugs claim 1 , recreational drugs claim 1 , antibiotics claim 1 , antimicrobials claim 1 , hormones claim 1 , hormone antagonists claim 1 , anticonvulsants claim 1 , gastrointestinal preparations claim 1 , dietary supplements claim 1 , and herbals.5. The method of claim 4 , wherein the drug is an ...

Self-assembling monomers and oligomers as surface-modifying endgroups for polymers

Polymers having the formula R(LE)wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, E is an endgroup covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain, having at least 5 identical repeat units, capable of self-assembly with L chains on adjacent molecules of the polymer, and the moieties (LE)in the polymer may be the same as or different from one another. Design of monomers, oligomers, or other reactive structures otherwise analogous to known Self Assembled Monolayers but with at least one reactive chemical group capable of binding them to the terminus of a polymer, so that the thiol-free SAM analogue becomes the self-assembling surface modifying endgroup of that polymer. Use of the polymer to fabricate a configured article from the surface-modified polymer or a coating or topical treatment on an article made from another material. 130.-. (canceled)31) A medical device or prosthesis comprising a polymer body , wherein the polymer body comprises a plurality of polymer molecules having the formula R(LE) , whereinR is a linear polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, x being 1 or 2, or R is a branched polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, x being 4,E is an endgroup that is covalently linked to polymeric core R by linkage L and E comprises a quaternary ammonium salt,{'sub': 2', '2, 'L is a divalent oligomeric chain having at least 5 identical repeat units, and L comprises an alkylene radical or (—CHCHO—), and L is capable of self-assembly with L chains on adjacent polymer molecules, and'}the moieties LE in the polymer may be the same as or different from one another.32) The medical device or prosthesis according to claim 31 , wherein L is an alkylene radical.33) The medical device or prosthesis according to claim ...

POLYURETHANE-GRAFTED HYDROGELS

An article comprising two chemically grafted polymer layers comprising a hydrogel layer and an end-functionalized polyurethane layer. The invention also includes methods of making and using the article. 1. A method of making a material that can be attached to bone , comprising the steps of:applying a solution comprising a polyurethane precursor comprising reactive endgroups, solvent, photoinitiator and crosslinker to a first polyurethane that is grafted to a hydrogel;polymerizing the polyurethane precursor; andtreating with heat and convection to remove the solvent to yield a second polyurethane coated on a polyurethane grafted hydrogel.2. The method of wherein the second polyurethane comprises polycarbonate urethane or polyether urethane.3. The method of wherein the reactive endgroups comprise one or more of acrylamide claim 1 , acrylate claim 1 , allyl ether claim 1 , methacrylate claim 1 , and vinyl.4. The method of wherein the solvent comprises one or more of dimethyacetamide claim 1 , dimethyl sulfoxide claim 1 , and tetrahydrofuran.5. The method of wherein the applying step further comprises a salt.6. A method of attaching an article to a bone claim 1 , the article comprising a porous polyurethane comprising a photoinitiator and a crosslinker claim 1 , the method comprising the steps of:placing the porous polyurethane in apposition to the bone; andpolymerizing the porous polyurethane to attach the article to the bone.7. The method of further comprising causing the porous polyurethane to contact and flow into bone.8. The method of wherein the article further comprises a second polyurethane attached to the porous polyurethane.9. The method of wherein the article further comprises a hydrogel.10. The method of wherein the polymerizing step comprises exposing the porous polyurethane to UV light claim 6 , heat claim 6 , or a chemical initiator. This application is a divisional of U.S. application Ser. No. 13/905,028, filed on May 29, 2013, entitled “Polyurethane- ...

HYDROPHILIC INTERPENETRATING POLYMER NETWORKS DERIVED FROM HYDROPHOBIC POLYMERS

A composition of matter comprising a water-swellable IPN or semi-IPN including a hydrophobic thermoset or thermoplastic polymer and an ionic polymer, articles made from such composition and methods of using such articles. The invention also includes a process for producing a water-swellable IPN or semi-IPN from a hydrophobic thermoset or thermoplastic polymer including the steps of placing an ionizable monomer solution in contact with a solid form of the hydrophobic thermoset or thermoplastic polymer; diffusing the ionizable monomer solution into the hydrophobic thermoset or thermoplastic polymer; and polymerizing the ionizable monomers to form a ionic polymer inside the hydrophobic thermoset or thermoplastic polymer, thereby forming the IPN or semi-IPN. 1. An orthopedic implant device , said implant device comprising:an IPN or semi-IPN composition (A) having a hydrogel bearing side of a biostable polymer network (A1), wherein the biostable polymer network (A1) comprises a first gradient of the biostable polymer (A1), which biostable polymer network (A1) decreases in concentration from the hydrogel bearing side to a bone interface surface; anda second gradient of a biostable polyurethane network (A2), which polyurethane network (A2) increases in concentration from the hydrogel bearing side to the bone interface surface, the bone interface surface of the polyurethane network (A2) comprises an osteochondral graft, wherein the orthopedic implant device is a cartilage replacement prosthesis.2. The orthopedic implant device of claim 1 , wherein the biostable polymer is polyacrylic acid without polyethelene glycol.3. The orthopedic implant device of claim 1 , wherein at least one of the networks (A1 or A2) is a covalently cross-linked network4. The orthopedic implant device of claim 2 , wherein the polyacrylic acid (A1) network is covalently cross-linked.5. The orthopedic implant device of claim 1 , further comprising an antioxidant.6. The orthopedic implant device of ...

METHOD FOR REMOVING BACTERIA FROM BLOOD USING HIGH FLOW RATE

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates. 1. An ex vivo method for removing bacteria from a sample taken from a subject who is suspected of being infected with bacteria , the method comprising:contacting a sample taken from the subject with an adsorption media to allow the formation of an adhering complex, wherein the adhering complex comprises bacteria and the adsorption media; andseparating the sample from the adhering complex to produce the sample with a reduced amount of bacteria.2. The method of claim 1 , wherein the sample is selected from the group consisting of whole blood claim 1 , serum and plasma.3. The method of claim 2 , wherein the sample is whole blood.4. The method of claim 1 , wherein the adsorption media is a solid substrate of high surface area having a hydrophilic surface that is free of a polysaccharide adsorbent.5. The method of claim 4 , wherein the solid substrate comprises a plurality of rigid polymer bead.6. The method of claim 5 , wherein the rigid polymer bead is a member selected from the group consisting of polyurethane claim 5 , polymethylmethacrylate claim 5 , polyethylene or co-polymers of ethylene and other monomers claim 5 , polyethylene imine claim 5 , polypropylene claim 5 , and polyisobutylene.7. The method of claim 4 , wherein the solid substrate comprises one or a plurality of hollow fibers.8. The method of claim 4 , wherein the solid substrate comprises solid fibers or woven yarn made from solid fibers.9. The method of claim 4 , wherein the hydrophilic surface is a cationic surface.10. The method of claim 1 , wherein the adsorption media has a high surface area as a result of surface or ...

BLOOD FILTRATION SYSTEM CONTAINING MANNOSE COATED SUBSTRATE

A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin. 1. A method for attaching a mannose to an amine containing substrate , said method comprising:contacting an aminated substrate with an aqueous solution containing a mannose to form a Schiff base intermediate; andcontacting the Schiff base with a reducing agent to attach said mannose.2. The method of claim 1 , wherein said mannose is a reducing sugar.3. The method of claim 1 , wherein said mannose is a nonreducing sugar.4. The method of claim 1 , wherein said mannose is a member selected from the group consisting of D-mannose claim 1 , L-mannose claim 1 , p-aminophenyl-α-D-mannopyranoside claim 1 , a mannose containing polysaccharide and mannan.5. The method of claim 4 , wherein said mannose is D-mannose.6. The method of claim 4 , wherein said mannose is mannan.7. The method of claim 1 , wherein said mannose is a nonreducing sugar.8. The method of claim 4 , wherein said method further comprises attaching an intermediate aldehyde to the amine substrate prior to said nonreducing mannose.9. The method of claim 1 , wherein said aqueous solution is acidic.10. The method of claim 1 , wherein said aminated substrate is an aminated bead.11. The method of claim 1 , wherein said reducing agent is a member selected from sodium cyanoborohydride and sodium borohydride.12. The method of claim 1 , wherein said method further comprises reacting heparin having a reactive aldehyde functionality.13. A bead having end point attached mannose made according to the method of .14. A bead having end point attached mannose and heparin made according to the method of . The present application is a divisional of U.S. patent application Ser. No. 14/973,617, filed Dec. 17, 2015 which is a continuation of PCT/US2014/043358, filed Jun. 20, 2014, which application claims ...

Device and method for restoration of the condition of blood

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE

The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein. 1. A method for augmenting impaired glycocalyx barrier function in a subject in need thereof , the method comprising:contacting a sample from the subject with a glycocalyx-mimetic adsorption media to enhance and/or restore the impaired glycocalyx barrier function, thereby treating the sample; andinfusing the treated sample into the subject,wherein the glycocalyx-mimetic adsorption media is a solid substrate having an adsorbent, wherein the adsorbent is a glycosaminoglycan comprising heparin, heparan sulfate, or a mixture thereof.2. The method of claim 1 , wherein the adsorbent is a glycosaminoglycan mixture comprising from about 40% to about 96% w/w heparan sulfate and/or heparin claim 1 , and claim 1 , optionally claim 1 , one or more of the following additional adsorbents: from about 5% to about 30% w/w chondroitin sulfate claim 1 , from about 1% to about 25% w/w dermatan sulfate claim 1 , from about 0.01% to about 20% w/w keratan sulfate claim 1 , and/or from about 5% to about 50% w/w hyaluronic acid.3. The method of claim 1 , wherein the glycocalyx-mimetic adsorption media aids in a member selected from the group consisting of vascular permeability claim 1 , adhesion of leucocytes claim 1 , adhesion of platelets claim 1 , mediation of shear stress ...

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods. 1. A method for concentrating a pathogen present in a biological sample obtained from a subject who is suspected of being infected with said pathogen , the method comprising:(a) contacting the biological sample obtained from the subject with an adsorption media under conditions to form an adhering complex comprising the adsorption media and said pathogen;(b) separating the adhering complex from components of the sample that are not included in the complex while maintaining the complex; and(c) collecting pathogens of the adhering complex.2. The method of claim 1 , wherein the biological sample is selected from the group consisting of whole blood claim 1 , serum claim 1 , plasma claim 1 , urine claim 1 , feces claim 1 , sputum claim 1 , tears claim 1 , saliva claim 1 , bronchial lavage fluid claim 1 , other bodily fluid claim 1 , and combinations thereof.3. The method of claim 2 , wherein the biological sample is a whole blood sample.4. The method of claim 2 , wherein (i) the whole blood sample is returned back to the subject before step (b) of claim 2 , and (ii) an additional whole blood sample is used to repeat step (a) claim 2 , to contact the additional whole blood sample on the adsorption media to thereby concentrate the pathogen.5. The method of claim 4 , wherein steps (i) and (ii) can be repeated 1 claim 4 , 2 claim 4 , 3 claim 4 , 4 claim 4 , 5 claim 4 , 6 or even more ...

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods. 1Borrelia,. An in vitro method for concentrating a pathogen present in a biological sample obtained from a subject who is suspected of being infected with said pathogen , wherein said pathogen comprises a bacteria of genus the method comprising:(a) contacting the biological sample obtained from the subject with an adsorption media under conditions to form an adhering complex comprising the adsorption media and said pathogen;(b) separating the adhering complex from components of the sample that are not included in the complex while maintaining the complex;(c) washing the adhering complex with a wash buffer; and(d) collecting pathogens of the adhering complex by applying an elution buffer to the complex, thereby concentrating the pathogen in an eluent.2Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia garinii,. The method of claim 1 , wherein the bacteria is selected from a group consisting of and any combination thereof.3. The method of claim 1 , wherein said pathogen further comprises a cellular byproduct of the bacteria responsible for causing an immune response syndrome associated with Jarisch-Herxheimer reaction in the subject.4. The method of claim 1 , wherein the wash buffer is a saline solution.5. The method of claim 1 , wherein the elution buffer is a high ionic strength or hypertonic saline solution.6. The method of claim 1 , wherein the biological ...

WEARABLE HEMOPERFUSION DEVICE

The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit. 1. A portable and/or wearable device for extracorporeal removal of a toxin and/or pathogen from blood of an individual infected with the toxin and/or pathogen , the device comprising a cartridge , said cartridge comprising an adsorption media ,wherein the adsorption media is a solid substrate of high surface area having at least one polysaccharide adsorbent on the surface thereof with a binding affinity or binding site for the toxin and/or pathogen such that when the flowing blood is in contact with said adsorption media, the toxin and/or pathogen bind to binding sites on the at least one polysaccharide adsorbent and become separated from blood.2. A portable and/or wearable extracorporeal hemoperfusion device , the device comprising:a cartridge comprising adsorption media, the cartridge having a first endplate and a second endplate;a blood influx port to allow blood to flow into the device; anda blood efflux port to allow blood to flow out of the device, wherein the blood flows through the first endplate through the adsorption media and out the blood efflux port.3. The portable and/or wearable device of claim 2 , further comprising a pump.4. The portable and/or wearable device of claim 3 , wherein the pump is a rotary pump.5. The portable and/or wearable device of claim 2 , further comprising a power source.6. The portable and/or wearable device of claim 2 , further comprising an electronic control module.7. The portable and/or wearable device of claim 6 , wherein the power source or the electronic control module are detachable.8. The portable and/or wearable device of claim 1 , wherein the least one polysaccharide adsorbent is selected from the group consisting of heparin claim 1 , ...

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods. 1. An in vitro method for concentrating infectious pathogens present in a biological sample obtained from a subject who is suspected of being infected with said pathogens , the method comprising:(a) contacting the biological sample obtained from the subject with an adsorption media under conditions to form an adhering complex comprising the adsorption media and said pathogens;(b) separating the adhering complex from components of the sample that are not included in the complex while maintaining the complex;(c) washing the adhering complex with a wash buffer; and(d) collecting pathogens of the adhering complex by applying an elution buffer to the complex, thereby concentrating the infectious pathogens in an eluent.2. The method of claim 1 , wherein the wash buffer is a saline solution.3. The method of claim 1 , wherein the elution buffer is a high ionic strength or hypertonic saline solution.4. The method of claim 1 , wherein the biological sample is selected from the group consisting of whole blood claim 1 , serum claim 1 , plasma claim 1 , urine claim 1 , feces claim 1 , sputum claim 1 , tears claim 1 , saliva claim 1 , bronchial lavage fluid claim 1 , other bodily fluid claim 1 , and combinations thereof.5. The method of claim 1 , wherein the adsorption media is a solid substrate of high surface area having at least one polysaccharide adsorbent on the surface thereof.6. The ...

BLOOD FILTRATION SYSTEM CONTAINING MANNOSE COATED SUBSTRATE

A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin. 1. A blood-filtration medium comprising:a substrate coated with mannose; andoptionally an anti-coagulation component.2. The medium of claim 1 , wherein said substrate comprises non-porous rigid beads claim 1 , particles claim 1 , or packing claim 1 , reticulated foams claim 1 , a rigid monolithic bed claim 1 , woven or nonwoven fabric claim 1 , yarn or solid or hollow dense claim 1 , monofilament fibers claim 1 , a flat film or barrier membrane claim 1 , a spiral wound cartridge formed from flat film or dense membrane.3. The medium of claim 1 , wherein said mannose is end-point attached to said substrate.4. The medium of claim 1 , wherein said anti-coagulation component is present claim 1 , and said anti-coagulation component is heparin.5. The medium of claim 4 , wherein said substrate comprises substrate coated with said heparin.6. The medium of claim 4 , wherein said substrate comprises non-porous rigid beads wherein a first portion of said beads is coated with mannose and a second portion of said is coated with heparin.7. The medium of claim 6 , wherein said mannose and said heparin are each end-point attached to said beads.8. The medium of claim 1 , wherein said heparin is heparin sulfate.9. The medium of claim 1 , wherein said mannose is D-mannose.10. The medium of claim 1 , wherein said mannose is a D-mannose polymer.11. A blood filtration cartridge that comprises a container which comprises the medium of .12. A system for filtering blood comprising:a container comprising a substrate coated with mannose;optionally an anti-coagulation component; andan extracorporeal blood filtration device, wherein said container is functionally coupled to the blood filtration device so that when in use the blood flows through the container and contacts ...

USE OF HEPARIN AND CARBOHYDRATES TO TREAT CANCER

The method is described as the removal of mediators that contribute to the pathogenesis of cancer from blood by contacting the blood with a solid, essentially non-micro-porous substrate which has been surface treated with heparin, heparan sulfate and, optionally, other molecules or chemical groups (the adsorbent media or media) having a binding affinity to the mediator, and wherein the size of the interstitial channels within said substrate are balanced with the amount of interstitial substrate surface area such that high flow rates of blood past said substrate creates a flow transport that is characterized by convection transport more than Brownian diffusion transport.

HYDROPHILIC INTERPENETRATING POLYMER NETWORKS DERIVED FROM HYDROPHOBIC POLYMERS

A composition having a hydrogel bearing side of a biostable polymer network, wherein the biostable polymer network comprises a first gradient of the biostable polymer, which biostable polymer network decreases in concentration from the hydrogel bearing side to a bone interface surface; and a second gradient of a biostable polyurethane network, which polyurethane network increases in concentration from the hydrogel bearing side to the bone interface surface, the bone interface surface useful for an orthopedic implant. 1. An orthopedic implant device , said implant device comprising:a composition comprising two or more polymer networks having a hydrogel bearing side of a polymer network, wherein the polymer network comprises a first gradient of the polymer, which polymer network decreases in concentration from the hydrogel bearing side to a bone interface surface; anda second gradient of a polyurethane network, which polyurethane network increases in concentration from the hydrogel bearing side to the bone interface surface, the bone interface surface of the polyurethane network comprises an osteochondral graft, wherein the orthopedic implant device is a cartilage replacement prosthesis.2. The orthopedic implant device of claim 1 , wherein the polymer is polyacrylic acid claim 1 , without polyethylene glycol.3. The orthopedic implant device of claim 1 , wherein at least one of the networks is a covalently cross-linked network.4. The orthopedic implant device of claim 1 , further comprising an antioxidant.5. The orthopedic implant device of claim 1 , further comprising water.6. The orthopedic implant device of claim 1 , wherein the polyurethane includes a pourous polyurethane claim 1 , which is a bone anchoring layer.7. The orthopedic implant device of claim 6 , wherein the porosity is made by incorporating a porogen into the polyurethane that is leached out.8. The orthopedic implant device of claim 7 , wherein the bone interface surface is a bone-like porous structure ...

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

METHOD FOR REMOVING BACTERIA FROM BLOOD USING HIGH FLOW RATE

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates. 117-. (canceled)18. An ex vivo method for removing bacteria from a sample taken from a subject who is. suspected of being infected with bacteria , wherein the bacteria are known to have a low affinity or no affinity for heparin or heparan sulfate , or its affinity to heparin or heparin sulfate is unknown , the method comprising:contacting a sample selected from the group consisting of whole blood, serum or plasma taken from the subject with an adsorption media to allow the formation of an adhering complex, wherein the adsorption media is a solid substrate of high surface area having at least one polysaccharide adsorbent comprising heparin or heparan sulfate on the surface thereof; andseparating the sample from the adhering complex to produce the sample with a reduced amount of bacteria.19. The method of claim 18 , wherein the sample is selected from the group consisting of whole blood claim 18 , serum and plasma.20. (canceled)21. The method of claim 18 , wherein the sample is whole blood.22. The method of claim 18 , wherein the solid substrate comprises a plurality of rigid polymer beads.23. The method of claim 22 , wherein the plurality of rigid polymer beads is a member selected from the group consisting of polyurethane claim 22 , polymethylmethacrylate claim 22 , polyethylene or co-polymers of ethylene and other monomers claim 22 , polyethylene imine claim 22 , polypropylene claim 22 , and polyisobutylene.24. The method of claim 22 , wherein the plurality of rigid polymer beads is polyethylene.25. The method of claim 22 , wherein the plurality of rigid polymer beads is polyethylene ...

Method for treating drug intoxication

Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject.

SURFACE MODIFICATION OF POLYMERS VIA SURFACE ACTIVE AND REACTIVE END GROUPS

Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively, a multifunctional coupling agent can be used to couple the primary reactive group to a second reactive group capable of reacting with a functional group associated with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, and polymers to attain specific surface properties. The invention involves bringing reactive endgroups to the surface with surface active spacer attached to the polymer chain end. The surface active spacer allows the migration and enrichment of reactive end groups to the surface during fabrication. The invention provides medical devices having a bio-interface with anti-thrombogenic properties, lubricity, selective adsorption, and antimicrobial properties. 1. A method of modifying a surface on a polymeric substrate selected from the group consisting of solid synthetic polymers , solid natural polymers , and hydrogels , comprising the steps of:fabricating an article from a polymeric body composed of polymeric molecules having first reactive endgroups linked to surface active spacers which surface active spacers comprise endgroups on said polymeric molecules and forming a surface of said first reactive endgroups linked to surface active spacers on said polymeric body;contacting the surface of said polymeric body with a compound containing at least one third reactive endgroup and at least one fourth reactive endgroup to react said at least one third reactive endgroup with a first reactive endgroup and thereby link said at least one fourth reactive endgroup to the polymeric molecules by a covalent or ionic bond; andcontacting the resulting surface of said polymeric body with a ...

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

WEARABLE HEMOPERFUSION DEVICE

The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit. 1. A ex vivo method for reducing a toxin and/or pathogen in the blood of an individual infected with the toxin and/or pathogen , the method comprising:a) passing blood from the individual through a device comprising an adsorption media, wherein the adsorption media and toxins and/or pathogens in the blood form an adhering complex;b) separating the resulting blood from the adhering complex to produce blood with a reduced level of the toxin and/or pathogen; andc) infusing the blood with the reduced level of the toxin and/or pathogen into the individual.2. The method of claim 1 , wherein the blood is selected from the group consisting of whole blood claim 1 , serum and plasma.3. The method of claim 2 , wherein the blood is whole blood.4. The method of claim 1 , wherein the adsorption media is a solid substrate of high surface area having at least one polysaccharide adsorbent.5. The method of claim 4 , wherein the least one polysaccharide adsorbent is selected from the group consisting of heparin claim 4 , heparan sulfate claim 4 , hyaluronic acid claim 4 , sialic acid claim 4 , carbohydrates with mannose sequences claim 4 , chitosan claim 4 , and a combination thereof.6. The method of claim 4 , wherein the least one polysaccharide adsorbent is heparin.7. The method of claim 4 , wherein the solid substrate comprises a plurality of rigid polymer bead.8. The method of claim 7 , wherein the rigid polymer bead is selected from the group consisting of polyurethane claim 7 , polymethylmethacrylate claim 7 , polyethylene or co-polymers of ethylene and other monomers claim 7 , polyethylene imine claim 7 , polypropylene claim 7 , and polyisobutylene.9. The method of claim 4 , wherein the solid ...

METHODS FOR REMOVING CYTOKINES FROM BLOOD WITH SURFACE IMMOBILIZED POLYSACCHARIDES

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media. 1. A device for removing an adsorbate selected from cytokines , pathogens and toxins from blood , the device comprising: a container which comprises a solid substrate of high surface area having at least one polysaccharide adsorbent on the surface thereof with a binding affinity for the adsorbate , wherein the at least one polysaccharide comprises a carbohydrate with mannose sequences; andwherein the solid substrate has interstitial channel spaces large enough to permit the transport of blood cells, and during blood flow the adsorbate binds to binding sites on the at least one polysaccharide adsorbent becoming separated from the blood and the transport of the adsorbates from blood to adsorbent sites on the solid substrate is primarily by convection transport.2. The device of claim 1 , wherein the solid substrate is a member selected from the group consisting of beads claim 1 , fibers claim 1 , reticulated foams claim 1 , and spiral-wound dense membranes.3. The device of claim 2 , wherein the solid substrate is comprises a plurality of rigid polymer beads.4. The device of claim 3 , wherein the rigid polymer beads are rigid polyethylene beads.5. The device of claim 4 , wherein the beads have a diameter ranging from 100 to 450 microns.6. The device ...

Silicone hydrogels for tissue adhesives and tissue dressing applications

A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone hydrogel formulation may be pre-formed as a film or other structure, or it may be polymerized during application as in the case of an adhesive formulation. A wound dressing comprising a silicone hydrogel formed as a film, either prior to application to a wound or in situ on a wound, which film has gas permeability, moisture permeability, and high water content, wherein said silicone hydrogel is formed from a polymerizable silicone such as a difunctional polydimethylsiloxane methacrylate and crosslinking agents such as N,N-dimethyllacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), and trimethylsiloxy silane (TRIS).

Control of polymer surface molecular architecture via amphipathic endgroups

Polymers whose surfaces are modified by endgroups that include amphipathic surface-modifying moieties. An amphipathic endgroup of a polymer molecule is an endgroup that contains at least two moieties of significantly differing composition, such that the amphipathic endgroup spontaneously rearranges its positioning in a polymer body to position the moiety on the surface of the body, depending upon the composition of the medium with which the body is in contact, when that re-positioning causes a reduction in interfacial energy. An example of an amphipathic surface-modifying endgroup is one that has both a hydrophobic moiety and a hydrophilic moiety in a single endgroup. For instance, a hydrophilic poly(ethylene oxide) terminated with a hydrophilic hydroxyl group is not surface active in air when the surface-modifying endgroup is bonded to a more hydrophobic base polymer. If the hydroxyl group on the oligomeric poly(ethylene oxide) is replaced by a hydrophobic methoxy ether terminus, the poly(ethylene oxide) becomes surface active in air, and allows the poly(ethylene oxide) groups to crystallize in the air-facing surface. In this example, immersion in water destroys the crystallinity as the poly(ethylene oxide) sorbs water and the hydrophobic methoxy group retreats below the surface of the polymer. Also disclosed are methods and articles of manufacture that make use of these polymers.

Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines

The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.

Use of heparin and carbohydrates for the treatment of cancer.

Blood filtration system containing mannose coated substrate

A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.

usable hemoperfusion device

a presente invenção refere-se a métodos e dispositivos para a remoção de toxinas e patógenos do sangue infectado de pacientes. em particular, os dispositivos são projetados para serem dispositivos extracorporais portáteis, utilizáveis, descartáveis e autocontidos que podem ser facilmente montados a partir de um kit. em uma modalidade, a presente invenção provê um dispositivo portátil e/ou utilizável para a remoção extracorpórea de uma toxina e/ou um patógeno do sangue de um indivíduo infectado com uma toxina e/ou um patógeno. The present invention relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, the devices are designed to be portable, usable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit. In one embodiment, the present invention provides a portable and / or usable device for the extracorporeal removal of a toxin and / or pathogen from the blood of an individual infected with a toxin and / or pathogen.

Method for treating drug intoxication

Hybrid polyurethane block copolymers with thermoplastic processability and thermoset properties

Block copolymers are formulated with multifunctional chain extenders. The block copolymers include a soft segment and a hard segment made from a diisocyanate, an alkylene diamine chain extender, and a multifunctional chain extender which provides delayed crosslinking. The multifunctional chain extenders have a functionality ≥3 and typically have at least one OH group. The multifunctional chain extenders may be aliphatic or aromatic triols or polyols, or may have other configurations, as described. The resulting block copolymers have improved mechanical properties such as compression set. They may be used in medical applications, or in industrial applications such as seal and gasket applications, including O-rings, window seals, and automotive gaskets. The initially-formed polyurethane resin behaves as a thermoplastic processable material, while the configured end-use product is thermoset.

Method for removing cytokines from blood with surface immobilized polysaccharides

Antimicrobial Polymers and Their Uses

Silicone hydrogels for tissue adhesives and tissue dressing applications

A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone hydrogel formulation may be pre-formed as a film or other structure, or it may be polymerized during application as in the case of an adhesive formulation. A wound dressing comprising a silicone hydrogel formed as a film, either prior to application to a wound or in situ on a wound, which film has gas permeability, moisture permeability, and high water content, wherein said silicone hydrogel is formed from a polymerizable silicone such as a difunctional polydimethylsiloxane methacrylate and crosslinking agents such as N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), and trimethylsiloxy silane (TRIS).

Methods for diagnosing infectious diseases using adsorption media

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

PDMS-PVP block copolymers

Methods for preparing functionalized polyvinylpyrrolidones with polymerizable functions. Also, amphipathic polydimethylsiloxane-PVP block copolymers, such as and (meth)acrylated and (meth)acrylamide-functionalized polyvinylpyrrolidone compounds, such as The block copolymers are useful as biomaterial components in biomedical devices. They provide improved wettability, lubricity, and material compatibility to the biomedical device, e.g., ophthalmic lenses.

Methods for diagnosing infectious diseases using adsorption media

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

Filtration media

The present disclosure provides a filtration media comprising a combination of (i) a hollow fiber membrane and (ii) adsorption media. The disclosure further provides a device, the device comprising a filtration media, which filtration media includes a combination of (i) a hollow fiber membrane and (ii) adsorption media.

Wearable hemoperfusion device

The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kitln one embodiment, the present invention provides a portable and/or wearable device for extracorporeal removal of a toxin and/or pathogen from blood of an individual infected with a toxin and/or pathogen.

Removal of virulence factors through extracorporeal therapy

A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as B. anthracis, S. aureus, and P. aeruginosa.

Blood filtration system containing mannose coated substrate.

Un método, sistema, dispositivo y medio de filtración de sangre para eliminar bacterias gram negativas de la sangre, en donde el medio incluye un substrato recubierto con manosa opcionalmente en constitución con un substrato recubierto con heparina.

Polyurethane-grafted hydrogels

An article comprising two chemically grafted polymer layers comprising a hydrogel layer and an end-functionalized polyurethane layer. The invention also includes methods of making and using the article.

Antimicrobial polymers and their uses

Polymers with non-leaching antimicrobial activity and their use as surface coatings or bulk resins for medical devices. The antimicrobial polymers are prepared with antimicrobial moieties covalently bonded to a polymer chain end or to a polymer backbone at a side chain end. The antimicrobial moiety-containing endgroups include surface active (or surface assembling) moieties which promote enrichment of antimicrobial endgroups at the polymer surface and thus formation of an antimicrobially active surface. Polymers with built-in antimicrobial endgroups can be used as bulk resins, as antimicrobial additives, or as infection preventative coatings in the manufacture of medical devices (e.g., catheters, vascular access devices, peripheral lines, IV sites, drains, gastric feeding and tubes, and other implantable devices). Such materials can also be used as antimicrobial and antifouling coatings on structures in contact with microorganism in environments that require control of biofilm formation, such as marine products.

Removal of virulence factors through extracorporeal therapy

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Device and method for restoration of the condition of blood

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Method for removing bacteria from blood using high flow rate

【課題】全血、血清又は血漿から、相当量の細菌を除去するための方法の提供。【解決手段】本発明は、吸着媒体を用いて、全血、血清又は血漿から、相当量の細菌（例えば、ヘパラン硫酸に対して親和性を有さない又は低い親和性を有する細菌を含む、グラム陰性菌及びグラム陽性菌）を除去するための方法を提供する。当該方法は高い体積流量及び高線流速を伴う体外処置に使用することができる。【選択図】図４

Removal of virulence factors through extracorporeal therapy

A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as B. anthracis, S. aureus, and P. aeruginosa.

Methods for diagnosing infectious diseases using adsorption media

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

Antimicrobial polymers and their uses

Method to eliminate bacteria from the blood using high flow

Un método ex vivo para eliminar bacterias de una muestra extraída de un sujeto que se sospecha que está infectado con bacterias, comprendiendo el método: poner en contacto una muestra extraída del sujeto con un medio de adsorción para permitir la formación de un complejo adherente, en el que el complejo adherente comprende bacterias y medio de adsorción; y separar la muestra del complejo adherente para producir la muestra con una cantidad reducida de bacterias. An ex vivo method for removing bacteria from a sample extracted from a subject suspected of being infected with bacteria, the method comprising: contacting a sample extracted from the subject with an adsorption medium to allow the formation of an adherent complex, in that the adherent complex comprises bacteria and adsorption medium; and separating the sample from the adherent complex to produce the sample with a reduced amount of bacteria.

Method for removing bacteria from blood using high flow rate

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

Device and method for restoration of the condition of blood

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Methods for diagnosing infectious diseases using adsorption media

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

Functionalized polyvinylpyrrolidone

Methods for preparation of functionalized polyvinylpyrrolidone with polymerizable functions and amphipathic polydimethylsiloxane-PVP block copolymers A (meth)acrylated polyvinylpyrrolidone compound and a (meth)acrylamide-functionalized polyvinylpyrrolidone structures are disclosed. The block copolymers are useful as biomaterial components in biomedical devices they provide improved wettability, lubricity, and material compatibility to the biomedical device, e.g, ophthalmic lenses.

Method for removing bacteria from blood using high flow rate

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

methods for diagnosing infectious diseases using adsorption medium

a presente invenção refere-se a um método in vitro para concentrar patógenos infecciosos encontrados em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os patógenos. é também fornecido no presente documento um método in vitro para reduzir ou eliminar células sanguíneas de uma amostra obtida a partir de um indivíduo sob suspeita de estar infectado com um patógeno infeccioso. a presente invenção também fornece um método para diagnosticar malária e um método para determinar se um indivíduo está infectado com um patógeno. é também fornecido no presente documento um concentrador e um kit para uso com os métodos. The present invention relates to an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual suspected of being infected with the pathogens. Also provided herein is an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected of being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Also provided herein is a concentrator and a kit for use with the methods.

Surface modification of polymers via surface active and reactive end groups

Surface modification of polymers via surface active and reactive end groups

Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively, a multifunctional coupling agent can be used to couple the primary reactive group to a second reactive group capable of reacting with a functional group associated with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, and polymers to attain specific surface properties. The invention involves bringing reactive endgroups to the surface with surface active spacer attached to the polymer chain end. The surface active spacer allows the migration and enrichment of reactive end groups to the surface during fabrication. The invention provides medical devices having a bio-interface with anti-thrombogenic properties, lubricity, selective adsorption, and antimicrobial properties.

Device and method for restoration of the condition of blood

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Method for treating drug intoxication

Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject.

Filtration media

The present disclosure provides a filtration media comprising a combination of (i) a hollow fiber membrane and (ii) adsorption media. The disclosure further provides a device, the device comprising a filtration media, which filtration media includes a combination of (i) a hollow fiber membrane and (ii) adsorption media.

Filtration media

The present disclosure provides a filtration media comprising a combination of (i) a hollow fiber membrane and (ii) adsorption media. The disclosure further provides a device, the device comprising a filtration media, which filtration media includes a combination of (i) a hollow fiber membrane and (ii) adsorption media.

Method for removing bacteria from blood using high flow rate

The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.

Filtration media

The present disclosure provides a filtration media comprising a combination of (i) a hollow fiber membrane and (ii) adsorption media. The disclosure further provides a device, the device comprising a filtration media, which filtration media includes a combination of (i) a hollow fiber membrane and (ii) adsorption media.

Medios de filtracion.

La presente divulgación proporciona un medio de filtración que comprende una combinación de (i) una membrana de fibra hueca y (ii) un medio de adsorción. La divulgación proporciona además un dispositivo, comprendiendo el dispositivo un medio de filtración, cuyo medio de filtración incluye una combinación de (i) una membrana de fibra hueca y (ii) un medio de adsorción.

Meio de filtração

meio de filtração. a presente invenção refere-se a um meio de filtração compreendendo uma combinação de (i) uma membrana de fibra oca e (ii) um meio de adsorção. a descrição fornece ainda um dispositivo, o dispositivo compreendendo um meio de filtração, o qual inclui uma combinação de (i) uma membrana de fibra oca e (ii) um meio de adsorção.

Filtration media

The present disclosure provides a filtration media comprising a combination of (i) a hollow fiber membrane and (ii) adsorption media. The disclosure further provides a device, the device comprising a filtration media, which filtration media includes a combination of (i) a hollow fiber membrane and (ii) adsorption media.

Filtration media

The present disclosure provides a filtration media comprising a combination of (i) a hollow fiber membrane and (ii) adsorption media. The disclosure further provides a device, the device comprising a filtration media, which filtration media includes a combination of (i) a hollow fiber membrane and (ii) adsorption media.

Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit

Polymers with bio-functional self assembling monolayer endgroups for therapeutic applications and blood filtration

Medical device, prosthesis, or packaging assembly made up of polymer body comprising at least one polymer having the formula R(LE)x wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons, and having x endgroups, x is an integer ≥ 1, E is an endgroup which is covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain which has at least 5 repeat units and which can self-assembly with L chains on adjacent molecules of the polymer, and moieties L and/or E in the polymer(s) may be the same as or different from one another in composition and/or molecular weight. The polymer body includes plural polymer molecules located internally within the body, at least some of which internal polymer molecules have endgroups that form a surface of the body. The surface endgroups include at least one self-assembling moiety.

Método para modular estrutura glicocalyx endotelial

método para modular estrutura glicocalyx endotelial. a presente invenção refere-se aos métodos e dispositivos para aumentar a função de barreira de glicocalyx comprometida, em um sujeito com necessidade dos mesmos, contatando a amostra (por exemplo, sangue) obtida do sujeito, com um meio de adsorção de glicocalyx mimético. o meio de adsorção inclui estruturas de glicosaminoglicano e, opcionalmente, proteínas do núcleo de proteoglicano, que são condutoras para intensificar e/ou restaurar a função de barreira de glicocalyx comprometida em uma amostra. a amostra contatada é, subsequentemente, separada do meio de adsorção, produzindo uma amostra tratada que pode ser infusa no sujeito. métodos e dispositivos para tratar um paciente que sofre de uma doença associada com a disfunção da barreira de glicocalyx, são também fornecidos aqui no presente.

Method for modulating endothelial glycocalyx structure

The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein.

Filtration media

Method for modulating endothelial glycocalyx structure

The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein.